Arctigenin induces the apoptosis of primary effusion lymphoma cells under conditions of glucose deprivation

YUSUKE BABA, ZENPEI SHIGEMI, NAOKO HARA, MISATO MORIGUCHI, MARINA IKEDA, TADASHI WATANABE and MASAHIRO FUJIMURO

Department of Cell Biology, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan

Received September 19, 2017; Accepted November 21, 2017

DOI: 10.3892/ijo.2017.4215

Abstract. Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of primary effusion lymphoma (PEL) and Kaposi's sarcoma. PEL is a type of non-Hodgkin's B-cell lymphoma, affecting immunosuppressed individuals, such as post-transplant or AIDS patients. However, since PEL is resistant to chemotherapeutic regimens, new effective treatment strategies are required. Arctigenin, a natural lignan compound found in the plant *Arctium lappa*, has been widely investigated as a potential anticancer agent in the clinical setting. In the present study, we examined the cytotoxic effects of arctigenin by cell viability assay and found that arctigenin markedly inhibited the proliferation of PEL cells compared with KSHV-uninfected B-lymphoma cells under conditions of glucose deprivation. Arctigenin decreased cellular ATP levels, disrupted mitochondrial membrane potential and triggered caspase-9-mediated apoptosis in the glucose-deprived PEL cells. In addition, western blot analysis using phospho-specific antibodies were used to evaluate activity changes in the signaling pathways of interest. As a result, arctigenin suppressed the activation of the extracellular signal-regulated kinase (ERK) and p38 mitogen-activated protein kinase (p38 MAPK) signaling pathways by inhibiting ERK and p38 MAPK phosphorylation in the glucose-deprived PEL cells. We confirmed that an inhibitor of ERK (U0126) or p38 MAPK (SB202190 and SB203580) suppressed the proliferation of the BC3 PEL cells compared with the KSHV-negative DG75 cells. Moreover, RT-PCR and luciferase reporter assay revealed that arctigenin and p38 MAPK inhibition by SB202190 or SB203580 downregulated the transcriptional expression of unfolded protein response (UPR)-related molecules, including GRP78 and ATF6α under conditions of glucose deprivation. Finally, we confirmed that arctigenin did not affect KSHV replication in PEL cells, suggesting that arctigenin treatment for PEL does not contribute to the risk of de novo KSHV production. These data thus indicate that arctigenin may serve as a lead compound for the development of novel and effective drugs for the treatment of PEL.

Introduction

Primary effusion lymphoma (PEL) is a rare subtype of large B-cell lymphoma and strongly linked with Kaposi's sarcoma-associated herpesvirus (KSHV) infection (1,2). PEL is also termed body cavity-based lymphoma, and is classified as a type of non-Hodgkin's B-cell lymphoma affecting with immunocompromised patients, such as AIDS patients or those who have undergone organ transplantation (1,2). PEL is usually present as a lymphomatous effusion in body cavities and is treated with CHOP therapy either alone or in combination with rituximab. However, PEL is resistant to these chemotherapy regimens (3), and is associated with a very poor prognosis (4-6). Currently, there is no effective treatment for PEL. KSHV, also known as human herpesvirus 8 (HHV8), is an oncogenic DNA virus and is classified in the γ-herpesvirus subfamily. As with other human herpesviruses, KSHV exists in either a latent or lytic infection state, which can persist long-term in the host after primary infection (7). During latency, the KSHV genome circularizes and forms a double-stranded episomal DNA molecule in infected cells such as PEL cells. KSHV expresses only a limited set of genes, including latency-associated nuclear antigen (LANA), v-FLIP, v-Cyclin and microRNAs, all of which strongly contribute to establishing latent infection (7,8). These viral molecules constitutively and/or transiently activate signaling pathways, including nuclear factor-κB (NF-κB), Akt, Wnt and extracellular signal-regulated kinase (ERK),

Correspondence to: Professor Masahiro Fujimuro, Department of Cell Biology, Kyoto Pharmaceutical University, Misasagi-Shichonocho 1, Yamashinaku, Kyoto 607-8412, Japan

E-mail: fuji2@mb.kyoto-phu.ac.jp

Abbreviations: ATF6α, activating transcription factor 6α; ATP, adenosine triphosphate; EDEM, ER degradation enhancing α-mannosidase-like protein; ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinase; GRP78, glucose-regulated protein 78; BiP, immunoglobulin heavy-chain-binding protein; JNK, c-Jun N-terminal kinase; KSHV, Kaposi's sarcoma-associated herpesvirus; NaB, sodium butyrate; p38 MAPK, p38 mitogen-activated protein kinase; PEL, primary effusion lymphoma; UPR, unfolded protein response

Key words: arctigenin, activating transcription factor 6, extracellular signal-regulated kinase, endoplasmic reticulum stress, glucose-regulated protein 78, Kaposi's sarcoma-associated herpesvirus, lignan, p38 mitogen-activated protein kinase, primary effusion lymphoma, unfolded protein response
which are essential for the malignant phenotype and cell survival of PEL (8-10). After re-activating the lytic infection state, most viral genes are expressed, and these viral gene products facilitate viral replication and the production of mature virions (11). We previously demonstrated that diallyl trisulfide, pyrrolidinium Cb fullerene, or sanguimycin induce the apoptosis of PEL cells via the inhibition of NF-κB (12), Akt (13), or ERK signaling (14), respectively. In addition, the unfolded protein response (UPR) pathway is downregulated in PEL cells; namely, IRE1α and PERK are downregulated under normal culture conditions (15). Therefore, endoplasmic reticulum (ER)-stress inducers, including methylseleninic acid, sodium selenite and thapsigargin cause severe ER stress and subsequent apoptosis through pro-apoptotic UPR activation in PEL cells (15,16).

Arctigenin, a representative dibenzyldiarylactone lignin, is an extract from the burdock plant, Arctium lappa, whose seed has traditionally been used in Japanese Kampo medicine for detoxification and inflammation, including in mastitis. Arctigenin has been reported to exhibit many biological functions, such as anticancer, anti-inflammatory (17), antiviral (18,19), immunomodulatory, antioxidant (20), neuroprotective (20) and anti-adipogenic (21) activities, and has been shown to modulate cell signaling pathways, such as signal transducer and activator of transcription 3 (STAT3) (22), Akt (23,24), NF-κB (24), p38 mitogen-activated protein kinase (p38 MAPK) (25,26) and ERK (24,27). In addition to affecting cell signaling, arctigenin influences ER stress and inhibits or activates the UPR, resulting in apoptosis or protection against ER stress (28-30). Arctigenin has been shown to exhibit anticancer activity in numerous types of cancer, including hepatocellular carcinoma (23), colon cancer (25), gastric cancer (31), pancreatic cancer (32), gallbladder cancer (27), breast cancer (24,26), ovarian cancer (33) and pancreatic cancer (34,35). One of the interesting anticancer properties of arctigenin is that it can preferentially induce the apoptosis of cancer cells under conditions of glucose starvation (34,36). Furthermore, arctigenin (GBS-01) has presented apoptosis of cancer cells under conditions of glucose starvation (34,35). One of the interesting anticancer properties of arctigenin is that it can preferentially induce the apoptosis of cancer cells under conditions of glucose starvation (34,36). Furthermore, arctigenin (GBS-01) has presented apoptosis of cancer cells under conditions of glucose starvation (34,36). Furthermore, arctigenin (GBS-01) has presented apoptosis of cancer cells under conditions of glucose starvation (34,36). Furthermore, arctigenin (GBS-01) has presented apoptosis of cancer cells under conditions of glucose starvation (34,36). Furthermore, arctigenin (GBS-01) has presented apoptosis of cancer cells under conditions of glucose starvation (34,36). Furthermore, arctigenin (GBS-01) has presented apoptosis of cancer cells under conditions of glucose starvation (34,36). Furthermore, arctigenin (GBS-01) has presented apoptosis of cancer cells under conditions of glucose starvation (34,36). Furthermore, arctigenin (GBS-01) has presented apoptosis of cancer cells under conditions of glucose starvation (34,36).

Materials and methods

Cell lines and reagents. KSHV-positive PEL cell lines (BC3, BCBL1, BC2 and HBL6) are derived from patients with PEL. PEL and KSHV-negative B-lymphoma cell lines (JBAB, Ramos and DG75) were kindly provided by Dr S.D. Hayward (Johns Hopkins University School of Medicine, Baltimore, MD, USA) and were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum. 2-Deoxyglucose, was dissolved in distilled sterile water, and arctigenin (both from Wako, Osaka, Japan), SB203580 (p38 MAPK inhibitor; Nacalai Tesque, Kyoto, Japan), SB202190 (p38 MAPK inhibitor; Nacalai Tesque) and U0126 (ERK inhibitor; Cell Signaling Technology, Beverly, MA, USA) were dissolved in dimethyl sulfoxide (DMSO).

Cell viability assay. The PEL cells and KSHV-negative cells were maintained in RPMI-1640 medium supplemented with 10% FCS. The cells were seeded in 96-well plates at 1x10⁴ cells/well in 100 µl of RPMI-1640 (or glucose-free RPMI-1640) with or without the compound at various concentrations and incubated for 24 h. The number of viable cells was estimated using Cell Count Reagent SF (Nacalai Tesque), as previously described (12). The optical density at 450 nm of each sample was measured using a microplate spectrophotometer (Tecan M200; Tecan, Kanagawa, Japan) and expressed as a percentage of the value obtained from untreated cells (defined as 100%).

Cell viability assay in the presence of 2-deoxyglucose. The cells (1x10⁴ cells/well) were seeded onto 96-well plates in 100 µl of RPMI-1640 medium. The cells were incubated in medium with 0, 1, 10, 50, 100 or 1,000 µM 2-deoxyglucose for 24 h (Fig. 2A), or with 0, 0.1, 2.5, 5, 10 or 20 µM arctigenin in combination with 100 µM 2-deoxyglucose for 24 h (Fig. 2B). The number of viable cells was evaluated using Cell Count Reagent SF (Nacalai Tesque).

Western blot analysis and antibodies. The cells (1x10⁶ cells) were lysed in 200 µl of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) sample buffer containing 0.5 mM phenylmethylsulfonyl fluoride, 1 µg/ml pepstatin, 5 µg/ml aprotonin and 1% 2-mercaptoethanol, boiled for 5 min, and sonicated for 30 sec with an immersible tip-type sonicator in order to shear the chromosomal DNA. The resulting lysate was subjected to SDS-PAGE on 8 or 12% polyacrylamide gel followed by western blot analysis. The proteins were transferred onto a ClearTrans nitrocellulose membrane (Wako) and, a membrane was incubated with 3% non-fat dry milk in phosphate-buffered saline (PBS) containing 0.1% Tween-20 (PBS-T) for 1 h at room temperature. The membrane was then incubated with the primary antibody (1,000-fold dilution) and subsequently with the secondary antibody (horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG antibody) (3,000-fold dilution) in Can Get Signal Immunoreaction Enhancer Solution (Toyobo, Osaka, Japan). The antibody-reactive bands were visualized by ECL Western Blotting Detection Reagents (GE Healthcare Life Sciences, Chicago, IL, USA), and the bands were visualized with X-ray film (Fujifilm Corp., Tokyo, Japan). The primary antibodies used in these experiments were as follows: β-actin (sc-69789), ribosomal protein S6 kinase A1/RSK-1 (sc-393147) and activating transcription factor (ATF)6α (H-280) (sc-22799) (all from Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), cleaved caspase-3 (#9661), cleaved caspase-9 (#9501), cleaved PARP (#9541), Thr202/Tyr204-phospho-ERK1/2 (#9101), Ser380-phospho-p90RSK (#11989) (all from Cell Signaling Technology, Danvers, MA, USA), Thr180/Tyr182-phospho-p38 MAPK (612288), phospho-p90RSK (611989) (all from Cell Signaling Technology, Danvers, MA, USA), Thr180/Tyr182-phospho-p38 MAPK (612288), p38 MAPK (612168), Thr183/Tyr185-phospho-SAPK/JNK (612540), SAPK/JNK (610627), Thr202/Tyr204-phospho-ERK1/2 (20A) (612359), Thr180/Tyr182-phospho-p38 MAPK (612288), p38 MAPK (612168), Thr183/Tyr185-phospho-SAPK/JNK (612540), SAPK/JNK (610627), Thr202/Tyr204-phospho-ERK1/2 (20A) (612359), ERK1/2 (610103) and pan ERK (610123) (all from BD Biosciences, Franklin Lakes, NJ, USA).

JC-1 staining for assessment of mitochondrial membrane potential. The inner mitochondrial membrane potential was evaluated by cell staining with JC-1 (PromoCell GmbH,
Heidelberg, Germany), a cationic fluorescent dye that exhibits a fluorescence emission shift upon aggregation from 530 nm (green 'JC-1 monomer') to 590 nm (red 'JC-1 aggregates'). In healthy cells with a high mitochondrial membrane potential, JC-1 enters the mitochondrial matrix in a potential-dependent manner and forms JC-1-aggregates, resulting in a red fluorescence signal, whereas mitochondrial damage induces mitochondrial depolarization and monomeric JC-1, resulting in a green fluorescence signal. The cells in a 96-well plate were cultured with 2 mg/ml JC-1 for 30 min and washed with PBS. The cells were then incubated with or without arctigenin for 30 min, and red fluorescence (535 nm excitation and 590 nm emission) were measured using a 96-well plate fluorometer (Tecan M200). The polarization of mitochondrial membrane potential, i.e., normality, are shown as the ratio of red/green fluorescence.

**Determination of cellular ATP concentration.** The cells were seeded in 96-well plates at 5x10^4 cells/well in 0.1 ml of medium and incubated with or without arctigenin for 3 h. The cellular ATP concentration was measured using the ATP assay reagent (Wako) according to the manufacturer’s instructions. Luminescence was measured using a luminescence microplate leader (Tecan M200). The ATP concentration of the untreated cells was defined as 100%.

**Cell viability assay using the kinase inhibitor.** The cells (1x10^5 cells/well) were cultured in 100 µl of glucose-free RPMI-1640 without or with the kinase inhibitors (U0126, SB202190 or SB203580) at various concentrations for 24 h. RPMI-1640 with or without the kinase inhibitors (U0126, SB202190 or SB203580) at various concentrations for 24 h. The number of viable cells was estimated using Cell Count reagent SF (Nacalai Tesque). The viability of cells was defined as 100%.

**Reverse transcription-polymerase chain reaction (RT-PCR).** Total RNA was purified and extracted from 1x10^6 cells using RNAiso Plus (Takara Bio Inc., Shiga, Japan), as previously described (12). First Strand cDNA was synthesized from 20 ng of total RNA using the ReverTra Ace qPCR RT kit (Toyobo). To quantify cDNA, polymerase chain reaction (PCR) was performed using GoTaq Flexi DNA Polymerase (Promega, Madison, WI, USA). The PCR products were analyzed by electrophoresis on 2% agarose gels and staining with ethidium bromide. The nucleotide sequences of oligonucleotides used for RT-PCR primers are shown in Table I.

**Luciferase reporter assay.** HeLa cells were obtained from RIKEN BioResource Center (Ibaragi, Japan) and used for transient transfection. HeLa cells (1x10^5) were transfected with 2 µg of a luciferase reporter plasmid containing either the promoter of the glucose-regulated protein 78 (GRP78)/BiP or the promoter of the ATF6 gene plasmid (pGL3-ATF6), together with 1 µg of a pSV-β-Gal plasmid (Promega) by the Chen and Okayama calcium-phosphate method (37). pGL3-Bip and pGL3-ATF6 which bear the promoter region of the GRP78/Bip gene and ATF6α gene upstream of the luciferase gene, respectively, were kind gifts from Takayanagi et al (38). pSV-β-Gal was used as an internal control for the determination of the transfection efficiency. The transfected cells were incubated in glucose-free medium with arctigenin (or kinase inhibitor) for 4 h. The cells were resuspended in 0.1 ml of lysis buffer for luciferase and β-Gal assay. Luciferase activity was measured using GloMax 20/20 luminometer (Promega). The luciferase activity divided by β-galactosidase activity in untreated cells cultured in glucose-free medium was defined as 100%.

**Real-time PCR for the measurement of viral production.** The measurement of lytic virus production was performed as previously described (12). Briefly, the BC3 cells were treated with 3 mM sodium butyrate (NaB) together with arctigenin for 48 h, and the culture media (300 µl) were harvested. To obtain only enveloped and encapsulated viral genomes, media were incubated with 20 units of DNase I (Wako) for 30 min, and viral DNA was purified using a QIAamp DNA blood mini kit (Qiagen, Hilden, Germany). Viral DNA was quantified by real-time PCR using an ORF50 (RTA)-specific primer set (forward, 5'-ATA ATC CGA ATG CAC ACA TCT TCC ACC AC-3' and reverse, 5'-TTC GTC GGC CTC TCG GAC GAA CTG A-3').

**Statistical analysis.** All data are presented as the means ± standard deviation (SD) from at least 3 independent experiments. Statistical significance was determined by one-way ANOVA.
followed by Tukey’s test for multiple comparisons using GraphPad PRISM 7 (GraphPad Software, La Jolla, CA, USA).

Results

Arctigenin exhibits preferential cytotoxicity against PEL cells under conditions of glucose deprivation. First, the proliferation of PEL cells and KSHV-uninfected B-cell lymphoma cells was measured in normal medium containing arctigenin, and the cytotoxicity was evaluated by analyzing the viability of the treated vs. the untreated cells (Fig. 1A). Arctigenin preferentially inhibited the proliferation of the PEL cell lines (BC3, BCBL1, BC2 and HBL6) compared with the KSHV-uninfected B-lymphoma cell lines (BJAB, Ramos and DG75). We then evaluated the cytotoxic effects of arctigenin on PEL cells cultured in glucose-free medium. Arctigenin preferentially inhibited the proliferation of the PEL cell lines (BC3, BC2, BCBL1 and HBL6) compared with the KSHV-uninfected B-lymphoma cell lines (BJAB, DG75 and Ramos). We then evaluated the cytotoxic effects of arctigenin on PEL cells cultured in glucose-free medium. As a result, at low concentrations (2-4 μM), arctigenin exerted preferential growth inhibitory effects on PEL cells (Fig. 1B). In particular, the viability of the BC3 and BCBL1 cells was decreased by 70% following treatment with 3 μM arctigenin in glucose-deprived medium (Fig. 1B). By contrast, a 100-fold greater concentration of arctigenin (300 μM) was needed to decrease the viability of these cells by 70% in glucose-containing media (Fig. 1A). The cytotoxic effects (CC50) of arctigenin on B-lymphoma cells under the glucose-supplied and glucose-deprived conditions are summarized in Table II. Arctigenin was active against not only the PEL (BC3, BCBL1, BC2 and HBL6), but also the KSHV-uninfected BJAB cells (Fig. 1A). These phenomena may be due to differences in the genetic background or differentiation status of the tested cells. Arctigenin exhibited potent anti-proliferative activities in the BC3 and BCBL1 cells in a dose- and glucose starvation-dependent manner, but did not have the same effects on the DG75 and Ramos cells. Therefore, we focused and analyzed the underlying molecular machinery in the BC3, BCBL1, Ramos and DG75 cells.

Combination of arctigenin and 2-deoxyglucose synergistically suppresses the proliferation of PEL cells. Arctigenin exhibited preferential cytotoxicity against the PEL cells under conditions of glucose deprivation. Therefore, we investigated whether treatment with a low concentration of arctigenin in combination with 2-deoxyglucose, a hexokinase inhibitor of glycolysis, inhibits the proliferation of PEL cells under...
caspase-9 activation, we examined whether arctigenin induces apoptosis via mitochondria.

To gain insight into the molecular mechanisms through which arctigenin induces apoptosis via mitochondrial membrane.

starved PEL cells by decreasing ATP levels and disrupting the mitochondrial membrane.

Arctigenin induces mitochondrial disruption in glucose-starved BC3 PEL cells. The BC3 and KSHV-uninfected Ramos cells cultured in glucose-free medium were treated with arctigenin for 30 min, and the inner mitochondrial membrane potential of the cells was evaluated by JC-1 staining. As a result, arctigenin preferentially depolarized the mitochondrial membrane in the BC3 cells compared with the Ramos cells, which was indicated by a decrease in the red/green ratio (Fig. 3B). To obtain further evidence of mitochondrial dysfunction induced by arctigenin, the effects of arctigenin on the cellular ATP concentration in glucose-starved BC3 and Ramos cell lines were examined (Fig. 3C and D). Treatment with 2-deoxyglucose (also termed 2-DG) was used for the glucose-starvation of the cells. The results revealed that cellular ATP production decreased to ~30% in both cell lines treated with arctigenin and 2-deoxyglucose (Fig. 3C), and arctigenin preferentially suppressed ATP production in BC3 cells cultured in glucose-free medium, compared with the Ramos cells (Fig. 3D). Thus, our data demonstrated that arctigenin impaired normal mitochondrial function and homeostasis in glucose-deprived PEL cells, resulting in the depolarization of mitochondrial membrane potential and a decrease in ATP production. Furthermore, mitochondrial disruption can induce caspase-9-mediated apoptosis. As regards cell viability (Fig. 2B) and ATP production (Fig. 3C) under glucose-supplied conditions, co-treatment with arctigenin and 2-deoxyglucose decreased the viability of the Ramos and BC3 cells. However, the co-treatment led to a decrease in ATP production in both the Ramos and BC3 cells to a varying extent, which may be due to differences in the ability of the cells to respond to ATP depletion or a difference in the inhibitory effect of 2-deoxyglucose on ATP production between the Ramos and BC3 cells.

**Arctigenin induces caspase-9-mediated apoptosis of glucose-starved PEL cells.** We then examined whether the anti-proliferative effects of arctigenin under conditions of glucose deprivation are due to apoptotic cell death. The PEL cells cultured in glucose-free medium were treated with or without 5 μM arctigenin and were then examined by western blot analysis using cleaved caspase and PARP antibodies (Fig. 3A). Active caspase-9 and -3 were detected in the arctigenin-treated BC3 PEL cells. In a time-dependent manner, the cleaved caspase-9, -3 and PARP fragments were increased in the glucose-starved BC3 cells treated with arctigenin, whereas modest cleaved caspase-9 and PARP were detected in the arctigenin-untreated BC3 cells. However, no significant cleavage of caspases and PARP was detected in the untreated BC3 cells cultured in glucose-containing medium. In addition, cleaved caspase-8 was not detected in the arctigenin-treated BC3 cells (data not shown).

Arctigenin induces mitochondrial disruption in glucose-starved PEL cells by decreasing ATP levels and disrupting the mitochondrial membrane. To gain insight into the molecular mechanisms through which arctigenin induces apoptosis via caspase-9 activation, we examined whether arctigenin induces mitochondrial disruption in glucose-starved BC3 PEL cells. The BC3 and KSHV-uninfected Ramos cells cultured in glucose-free medium were treated with arctigenin for 30 min, and the inner mitochondrial membrane potential of the cells was evaluated by JC-1 staining. As a result, arctigenin preferentially depolarized the mitochondrial membrane in the BC3 cells compared with the Ramos cells, which was indicated by a decrease in the red/green ratio (Fig. 3B). To obtain further evidence of mitochondrial dysfunction induced by arctigenin, the effects of arctigenin on the cellular ATP concentration in glucose-starved BC3 and Ramos cell lines were examined (Fig. 3C and D). Treatment with 2-deoxyglucose (also termed 2-DG) was used for the glucose-starvation of the cells. The results revealed that cellular ATP production decreased to ~30% in both cell lines treated with arctigenin and 2-deoxyglucose (Fig. 3C), and arctigenin preferentially suppressed ATP production in BC3 cells cultured in glucose-free medium, compared with the Ramos cells (Fig. 3D). Thus, our data demonstrated that arctigenin impaired normal mitochondrial function and homeostasis in glucose-deprived PEL cells, resulting in the depolarization of mitochondrial membrane potential and a decrease in ATP production. Furthermore, mitochondrial disruption can induce caspase-9-mediated apoptosis. As regards cell viability (Fig. 2B) and ATP production (Fig. 3C) under glucose-supplied conditions, co-treatment with arctigenin and 2-deoxyglucose decreased the viability of the Ramos and BC3 cells. However, the co-treatment led to a decrease in ATP production in both the Ramos and BC3 cells to a varying extent, which may be due to differences in the ability of the cells to respond to ATP depletion or a difference in the inhibitory effect of 2-deoxyglucose on ATP production between the Ramos and BC3 cells.
ERK (14,41,42) signaling pathways is necessary for KSHV to establish infection, maintain malignant phenotypes and ensure survival in host cells. Therefore, in this study, we investigated the effects of arctigenin treatment on MAPK signaling, including p38 MAPK, ERK and JNK, in cells cultured in glucose-deprived medium. The phosphorylation (i.e., activation) level of JNK was not markedly altered in the glucose-deprived cells by arctigenin (Fig. 4A), while the phosphorylation of p38 MAPK and ERK1/2 was decreased in the PEL cells (BC3 and BCBL1) treated with arctigenin for 4 and 6 h. In addition, we examined the phosphorylation of p90RSK, which is an ERK substrate. The phosphorylation of ERK1/2 was also confirmed by a different antibody. U0126 treatment was used as a control for the inhibition of MEK1/2/ERK1/2 signaling. Compared to the KSHV-uninfected Ramos and DG75 cells, arctigenin markedly decreased the phosphorylation of p90RSK and ERK1/2 in the glucose-deprived PEL cells in a dose-dependent manner (Fig. 4B). These results indicate that the apoptotic effects of arctigenin are related to the modulation of the ERK and p38 MAPK signaling pathways.

The inhibition of either ERK or p38 MAPK signaling suppresses the proliferation of glucose-deprived PEL cells.

Arctigenin led to a decrease in PEL cell proliferation through apoptosis (Figs. 1 and 3), and moreover suppressed ERK and p38 MAPK signaling (Fig. 4) in PEL cells under conditions of glucose deprivation. We therefore wished to examine the cytotoxic effects of a MEK inhibitor and p38 MAPK inhibitors on PEL cells to confirm that ERK and JNK signaling contribute to the survival and growth of PEL cells under conditions of glucose deprivation. U0126 is known to inhibit MEK1 and MEK2, which phosphorylate and activate ERK1/2. SB202190 and SB203580 inhibit p38 MAPK activity by competing with ATP for binding in the ATP-binding pocket of p38, respectively. When the BC3 PEL and KSHV-uninfected DG75 cells were treated with 50 µM U0126, 50 µM SB202190 or 100 µM SB203580 for 24 h, the viability of the glucose-deprived BC3 cells was decreased compared to that of the DG75 cells (Fig. 5). These data indicate that ERK and p38 MAPK signaling strongly contribute to the survival and proliferation of PEL cells. In addition, we evaluated the anti-proliferative effects of the inhibitors under glucose-supplied conditions. SB202190 and SB203580 did not exert any anti-proliferative effects on the PEL cells cultured in glucose-containing medium (data not shown). We have also previously reported the anti-proliferative effects of U0126 (13,14). The viability of the BC3 cells cultured...
Figure 4. Arctigenin suppresses ERK and p38 MAPK signaling in glucose-deprived PEL cells. (A) Western blot analysis of the phosphorylation of p38, ERK1/2, and JNK in arctigenin-treated B-lymphoma cells. PEL cells (BC3 and BCBL1) and infected Ramos cells were cultured in glucose-free medium with 5 µM arctigenin (Arc) for 4 or 6 h, or cultured without arctigenin for 4 h. Whole-cell lysates were subjected to western blot analysis with an anti Thr202/Tyr204-phospho-ERK1/2 (20A), Thr180/Tyr182-phospho-p38, p38, Thr183/Tyr185-phospho-JNK or JNK antibodies. (B) Western blot analysis of phosphorylated p90RSK in arctigenin-treated PEL cells. PEL and uninfected cells (Ramos and DG75) were cultured in glucose-free medium with 0, 5 or 10 µM arctigenin for 3 h, or BC3 cells were cultured in glucose-free medium with 50 µM U0126 for 3 h. U0126 was used as an inhibitor of MEK1/2-ERK1/2 signaling. Cell extracts were subjected to blotting with anti Ser380-phospho-p90RSK, p90RSK, Thr202/Tyr204-phospho-ERK1/2 (#9101), pan ERK, or ERK2 antibodies. The pan ERK antibody recognizes ERK1, 2 and 3. The arrowhead indicates phosphorylated ERK1/2.

Figure 5. Inhibition of either ERK or p38 MAPK signaling suppresses the proliferation of PEL cells under conditions of glucose deprivation. (A-C) Cytotoxic effects of U0126 (MEK1/2 inhibitor), SB 202190 (p38 MAPK inhibitor) and SB203580 (p38 MAPK inhibitor), respectively, on BC3 PEL and uninfected DG75 cells. U0126 is an inhibitor of MEK1/2, which phosphorylates and activates ERK1/2. BC3 and DG75 cells were incubated with various concentrations of U0126, SB202190 and SB203580 for 24 h and subjected to viability assays. The values of the respective untreated cells are set at 100%. *P<0.01, **P<0.001 and ***P<0.0001 indicate a statistically significantly difference compared with the untreated cells; ns, not significant.
Arctigenin and p38 MAPK inhibitor suppress the transcriptional expression of GRP78 and ATF6α in glucose-deprived PEL cells. (A) Effects of arctigenin on the mRNA expression of the UPR- and ER-stress related molecules. PEL cells (BC3 and BCBL1) and uninfected cells (Ramos and DG75) were treated with or without 5 µM arctigenin (Arc) for 4 or 6 h, and harvested. Total RNA was extracted from the cells and subjected to RT-PCR to detect the mRNA expression of EDEM2, EDEM1, GADD34, GRP94, CHOP, GRP78/Bip, ATF6α and GAPDH. (B and C) Effects of arctigenin and p38 MAPK inhibitor on the promoter activities of GRP78/Bip and ATF6α genes. HeLa cells transfected with the luciferase reporter plasmids containing the GRP78 or ATF6α promoter were cultured in glucose-free medium with 10 µM arctigenin, 100 µM SB203580 or 100 µM SB202190 for 4 h, and lysed in buffer for luciferase analysis. The promoter activities of GRP78 and ATF6α in drug-untreated and glucose-deprived cells is defined as 100% relative activity. *P<0.01 and **P<0.001 indicate a statistically significant difference compared with the untreated cell; ns, not significant. (D) The level of ATF6α protein in arctigenin-treated cells. BCBL1 and DG75 cells were incubated with glucose-free medium with 5 or 10 µM arctigenin for 6 h, and cell lysates were probed by blotting using an antibody that recognizes ATF6α N-terminal region and ATF6α cleaved form, p50 ATF6α (left panels). HeLa cells were transfected with N-terminal FLAG-tagged ATF6α by the Chen and Okayama calcium-phosphate method (37) and were treated with 5 µM arctigenin for 6 h. Cell lysates were subjected to blotting using Flag antibody (right panel).

with glucose was decreased by 60 and 25% following treatment with 100 and 50 µM of U1026, respectively (13,14).

Arctigenin and p38 MAPK inhibitor suppress the transcriptional expression of GRP78/Bip and ATF6α in glucose-deprived PEL cells. Arctigenin inhibited ERK and p38 MAPK signaling in glucose-deprived PEL cells (Fig. 4). Cytokines and forms of cellular stress, such as UV irradiation, heat shock and osmotic changes, have been known to activate p38 MAPK signaling, which correlates with the upregulation of the UPR including GRP78/Bip, CHOP and ATF6α (43,44). Furthermore, it has been reported that arctigenin blocks the UPR and the expression of GRP78, CHOP, ATF4 and XBP1 (28,29). Therefore, in this study, we investigated whether arctigenin downregulates the mRNA expression of ER stress-related molecules in PEL cells under conditions of glucose deprivation. GRP78 and GRP94 are ER stress-inducible ER chaperones. GRP78, also known as Bip, plays an essential role in the UPR (45). ER degradation enhancing α-mannosidase-like proteins (EDEM) are ER membrane proteins and are involved in ER-associated degradation (ERAD). EDEM1/2 targets misfolded glycoproteins for degradation in an N-glycan-dependent manner (45). ATF6α is a UPR-related transcription factor and activates the transcriptional expression of GRP78. CHOP is also an UPR-related transcription factor and transcriptionally upregulates GADD34 which induces a translation block (46). In this study, the mRNA expression levels of these molecules in cells cultured in glucose-free medium with (or without) arctigenin were measured by RT-PCR (Fig. 6A). Arctigenin increased the mRNA levels of GRP94 and CHOP in glucose-deprived PEL and uninfected cells. The expression of GADD34 was slightly upregulated in the arctigenin-treated BC3 and uninfected cells. In addition, GRP78 and ATF6α exhibited very low levels of transcription in all cell types in the absence of glucose; however, arctigenin decreased the transcription of GRP78 and ATF6α. By contrast, EDEM1 and EDEM2 exhibited high levels of transcription in all cell types, while arctigenin did not affect the transcription of these molecules.

As the mRNA expression levels of GRP78 and ATF6α were decreased in the arctigenin-treated cells, we examined whether arctigenin inhibits the transcription of these genes by a luciferase reporter assay using the promoter sequences of GRP78 or ATF6α. HeLa cells transfected with GRP78 or ATF6α promoter-driven luciferase reporter plasmids were incubated in glucose-free medium with arctigenin or p38 MAPK inhibitors (SB203580 and SB202190) for 4 h, and cell extracts were
subjected to measure luciferase activities. The results revealed that arctigenin markedly suppressed GRP78 and ATF6α promoter activities in the HeLa cells cultured in glucose-free medium (Fig. 6B and C). In addition to arctigenin, GRP78 promoter activity was decreased by ~40% by glucose depletion and either SB203580 or SB202190 treatment (Fig. 6B), while ATF6α promoter activity was decreased by ~70 and 50% by SB203580 or SB202190 treatment, respectively (Fig. 6C). These data indicate that arctigenin and p38 MAPK inhibition downregulate the mRNA expression of GRP78 and ATF6α under conditions of glucose deprivation. We then wished to elucidate whether arctigenin treatment alters the protein expression of ATF6α. The BCBL1 and DG75 cells were incubated in glucose-free medium with arctigenin, and the amount of ATF6α protein was detected by western blot analysis using an antibody that recognizes the N-terminal region of both full-length ATF6α and p50 ATF6α, which is the cleaved form of ATF6α containing the transcriptional activation domain (Fig. 6D, left panel). HeLa cells transfected with N-terminal Flag-tagged ATF6α were treated with arctigenin, and were then examined by western blot analysis using a Flag antibody (Fig. 6D, right panel). As a result, the amount of ATF6α protein was decreased in the arctigenin-treated BCBL1 and DG75 cells, and the amount of p50 ATF6α was also decreased in the arctigenin-treated DG75 and HeLa cells. These data suggest that arctigenin suppressed not only the expression of ATF6α, but also the production of p50 ATF6α.

**Effects of arctigenin on KSHV replication in PEL.** Previous studies have indicated that cellular stress, such as ER stress, oxidative stress and hypoxia, reactivates latent KSHV infection and induces lytic replication in PEL cells (47,48). Therefore, in this study, we evaluated whether arctigenin enhances (or suppresses) de novo KSHV production in BC3 PEL cells cultured in normal medium. BC3 cells were treated with 3 mM NaB in the presence or absence of arctigenin for 48 h, and the culture media were harvested. Viral DNA purified from culture media was quantified by real-time PCR (Fig. 7). NaB treatment was used for the induction of lytic replication.

As a result, NaB prominently increased viral production by the BC3 cells cultured in culture medium containing glucose; however, arctigenin neither enhanced nor suppressed viral production at 10 µM, which also did not affect BC3 cell growth (Fig. 1A). These results indicate that arctigenin may kill PEL cells without the risk of de novo KSHV infection and production.

**Discussion**

PEL is a rare subtype of large B-cell lymphoma associated with KSHV and it has the highest incidence rate in HIV-positive individuals. In the majority of cases, PEL is present as a malignant pleural, peritoneal or pericardial effusion without a detectable solid mass. However, in rare cases, solid variants of PEL are present as solid tumor masses or extracavitary solid tumors (49,50). In general, chemotherapeutic drugs targeting the proliferation machinery of tumor cells also damage proliferating normal cells, such as hematopoietic stem cells. Hence, the development of tumor-specific anticancer agents is required for safe and effective cancer therapy. The tumor tissue environment is known to lack oxygen and glucose compared with normal tissues. Thus, selectively targeting metabolically stressed (glucose-deprived) tumor cells, including PEL, may represent a promising strategy with which to inhibit tumor cell proliferation without affecting normal cells. In this regard, arctigenin has been shown to preferentially induce tumor growth suppression and apoptosis in glucose-deprived tumor cells (34-36). In this study, we examined a novel biological function of arctigenin and the molecular mechanisms through which it preferentially induces the apoptosis of glucose-starved PEL cells. We propose a model in which arctigenin downregulates MAPK signaling and induces mitochondrial disruption, leading to PEL cell death (Fig. 8).

Based on our understanding of KSHV-infected PEL and the biochemical properties of arctigenin, we hypothesize 3 possible mechanisms through which arctigenin induces the apoptosis of PEL cells under conditions of glucose deprivation: i) mitochondrial disruption; ii) suppression of the ERK and p38 MAPK pathways which are involved in the proliferation and survival of PEL cells; and iii) the suppression of ATF6α and GRP78 expression. We can surmise that the cytotoxic effects of arctigenin in glucose-deprived PEL cells may be mediated via a combination of these mechanisms.

Arctigenin has been shown to induce a decrease in ATP production (36,30,51) and mitochondrial membrane disruption (21,25,30) in glucose-deprived tumor cells. Previous studies have suggested that arctigenin inhibits complex I, II and IV of the mitochondrial respiratory chain (21,36,30) and consequently causes mitochondrial membrane disruption, which results in an increase in cytochrome c release and cytochrome c-related reactive oxygen species (ROS) production, thereby decreasing intrachromosome c release and cytochrome c-related reactive oxygen species (ROS) production.
In addition to mitochondrial damage, arctigenin has been known to cause cell cycle arrest or apoptosis by modulating various signaling pathways, including STAT3 (22), Akt (23, 24, 34), NF-κB (24), p38 MAPK (25, 26) and ERK (24, 27). MAPKs, including ERK, p38 MAPK and JNK, are involved in the development, proliferation and progression of cancer. In addition, p38 MAPK and JNK are also associated with various stress responses. ERK is mainly activated by growth factors, while p38 and JNK are activated by cytokines, growth factors and cellular stresses, such as ER stress, UV irradiation and heat shock (52). It has been reported that arctigenin activates p38 MAPK signaling, as well as ROS production (25, 26) and inhibits ERK signaling (24, 27). By contrast, other studies have found that arctigenin suppresses p38 MAPK signaling in lipopolysaccharide (LPS)-treated RAW264.7 cells (53, 54). In this study, our data are in line with these findings, in that ERK and p38 MAPK activation were suppressed by arctigenin in PEL cells under glucose-deprived conditions (Fig. 4). We hypothesize that these conflicting results of different studies as mentioned above may be due to differences in the genetic background of the tested cancer cells, KSHV infection, glucose conditions during viability assays, or the assayed arctigenin concentrations.

As described above, arctigenin treatment strongly perturbs cellular signaling cascades that are essential for KSHV to maintain a malignant phenotype and ensure survival in an infected cell, including PEL and Kaposi's sarcoma. The constitutive and/or transient activation of several signaling pathways, such as NF-κB, Akt, Wnt and ERK, is known to be necessary for KSHV to establish infection, maintain malignant phenotypes and cell survival in a host cell. In addition to mitochondrial disruption, arctigenin suppresses the ERK and p38 MAPK pathways in glucose-deprived PEL cells, resulting in the inhibition of cell proliferation. On the other hand, various cellular stresses activate p38 MAPK, which enhances the UPR, including the ATF6α along with the p38 MAPK-mediated phosphorylation and cleavage of ATF6α. Cleaved ATF6α (p50ATF6/ATF6-N) induces transcriptional activation of GRP78 and ATF6α itself. Arctigenin inhibits not only the p38 MAPK pathway, but also the expression of GRP78, ATF6α and p50 ATF6α. Hence, the suppression may be due to an increase in ER stress, which can cause the apoptosis of PEL cells.

Figure 8. Model of arctigenin-mediated inhibition of PEL cell growth. Arctigenin induced a decrease in ATP levels, the disruption of mitochondrial membrane potential and apoptosis via caspase-9 activation in PEL cells under conditions of glucose deprivation. Arctigenin-induced mitochondrial disruption correlates with caspase-9-mediated apoptosis. The ERK and p38 MAPK signaling pathways are known to be required for KSHV to establish infection, maintain malignant phenotypes and cell survival in a host cell. In addition to mitochondrial disruption, arctigenin suppresses the ERK and p38 MAPK pathways in glucose-deprived PEL cells, resulting in the inhibition of cell proliferation. On the other hand, various cellular stresses activate p38 MAPK, which enhances the UPR, including the ATF6α along with the p38 MAPK-mediated phosphorylation and cleavage of ATF6α. Cleaved ATF6α (p50ATF6/ATF6-N) induces transcriptional activation of GRP78 and ATF6α itself. Arctigenin inhibits not only the p38 MAPK pathway, but also the expression of GRP78, ATF6α and p50 ATF6α. Hence, the suppression may be due to an increase in ER stress, which can cause the apoptosis of PEL cells.
pathways (i.e., persistent infection, tumorigenicity, stress response and gene expression), thus resulting in growth inhibition and the apoptosis of PEL cells. It can also be hypothesized that the arctigenin-induced inhibitory effects on these kinases may lead to antitumor activities against KSHV-infected PEL, but not KSHV-uninfected B-lymphoma.

ER stress, such as ROS, misfolded proteins and denatured protein generation, leads to the UPR, which induces the expression of ER chaperones and ER-related molecules to facilitate the refolding or the degradation of misfolded proteins and to suppress the translation of de novo proteins. UPR is primarily regulated by GRP78, and consists of 3 pathways involving ATF6α, IRE1α and PERK (45). Under normal conditions, GRP78 interacts with and inactivates ATF6α, IRE1α and PERK, but dissociates from these during ER stress, which activates these pathways. In an ER stress-dependent manner, ER-localized ATF6α is translocated into the Golgi apparatus and is cleaved. Cleaved ATF6α (p50 ATF6α) is then translocated to the nucleus, which in turn activates the transcriptional expression of ER chaperones, such as GRP78, GRP94, XBP1, EDEM1/2 and ATF6α itself (45,46). IRE1 induces the splicing of immature XBP1 mRNA, and the translated XBP1 protein activates the transcription of GRP78 and XBP1 itself. PERK phosphorylates eIF2α, and induces a translation block. However, in the presence of severe ER stress, pro-apoptotic UPR is activated. Pro-apoptotic UPR activates the expression of the transcription factor, CHOP, which transcriptionally upregulates GADD34 and pro-apoptotic Bcl-2 proteins, leading to apoptosis (45,46). As for the association between arctigenin and UPR, arctigenin has been shown to induce ROS production (25,26,36) and ER stress along with the induction of GRP78 and CHOP in PEL cells (Fig. 6A).

In this study, we found that arctigenin suppressed the phosphorylation of ATF6α and p50 ATF6α in glucose-deprived PEL cells (Figs. 4 and 6). In addition, a p38 MAPK inhibitor also suppressed cell growth (Fig. 5B and C) and the promoter activities of the GRP78 and ATF6α genes (Fig. 6B and C) in glucose-deprived cells. These findings are consistent with previous studies, which indicate that the activation of p38 MAPK upregulates GRP78 expression (60,61), induces the phosphorylation and cleavage of ATF6α, and then activates p50 ATF6α in an ATF6α-phosphorylation-dependent manner (43,44). It can thus be hypothesized that arctigenin suppresses the p38 MAPK-mediated ATF6α activation (or cleavage), which in turn suppresses the ATF6α-mediated transcription of GRP78 and ATF6α itself. These disruptions of UPR can evoke severe ER stress and subsequent apoptosis through pro-apoptotic UPR activation, including CHOP and GADD34 expression in PEL cells (Fig. 6A).

In conclusion, the findings of this study demonstrate that arctigenin treatment induces mitochondrial disruption, the suppression of the ERK and p38 MAPK pathways, and the downregulation of ATF6α and GRP78 expression in glucose-deprived PEL cells. These phenotypes of arctigenin can serve as cytotoxic effectors in glucose-deprived PEL cells. Therefore, PEL cells are more sensitive to the anti-proliferative effects of arctigenin than KSHV-uninfected cells, thereby raising the possibility that arctigenin may serve as a novel therapeutic agent in the treatment of KSHV-associated lymphoma.

Acknowledgements

This study was supported in part by a Grant-in-Aid for Scientific Research (C) (15K07952), Young Scientists (B) (16K18925) and Strategic Research Foundation at Private Universities (S1311035) from MEXT of Japan, and by the Japan Agency for Medical Research and Development (16fk041070h0201). We would like to thank Dr Peter Gee (Kyoto University, Kyoto, Japan) for critically proofreading the manuscript.

References


